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Structural Basis for the Inhibition
of Caspase-3 by XIAP
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The activity of caspases can be ablated by naturalSummary
inhibitors. Indeed, viruses have adopted a successful
strategy to control the apoptotic response of the hostThe molecular mechanism(s) that regulate apoptosis
to viral infection by elaborating proteins that directlyby caspase inhibition remain poorly understood. The
inhibit caspases. For example, the poxvirus inhibitormain endogenous inhibitors are members of the IAP
CrmA rapidly inactivates caspases-1 and -8, and thefamily and are exemplified by XIAP, which regulates
baculovirus inhibitor p35 rapidly inhibits an even widerthe initiator caspase-9, and the executioner caspases-
profile of caspases (reviewed in Ekert et al., 1999). In3 and -7. We report the crystal structure of the second
each case, the target site on the inhibitor is in a well-BIR domain of XIAP (BIR2) in complex with caspase-
defined sequence that satisfies the substrate binding3, at a resolution of 2.7 A˚, revealing the structural basis
requirements of the target caspases, and the mecha-for inhibition. The inhibitor makes limited contacts
nism appears similar to substrate hydrolysis, with thethrough its BIR domain to the surface of the enzyme,
important exception that the enzyme active site isand most contacts to caspase-3 originate from the
trapped during the reaction (Zhou et al., 1997, 1998). NoN-terminal extension. This lies across the substrate
homologs of p35 have yet been found in animals, andbinding cleft, but in reverse orientation compared to
so far no animal homologs of CrmA have been found tosubstrate binding. The mechanism of inhibition is due
target caspases. Animals have adopted another proteinto a steric blockade prohibitive of substrate binding,
family to regulate caspase activity, namely the inhibitorand is distinct from the mechanism utilized by syn-
of apoptosis proteins (IAPs).thetic substrate analog inhibitors.
The IAP family is characterized by a conserved mod-
ule known as the BIR domain, and proteins containingIntroduction
this module have now been found throughout the eu-
karyotic kingdoms (Uren et al., 1998). Six human IAPsThe initiation and execution phases of apoptosis are
have been discovered, and at least four of them haveboth dependent on caspases, cytosolic cysteine prote-
been reported to directly inhibit caspases. They regulateases that cleave at Asp residues in their target sub-
apoptosis by preventing the action of the central execu-
strates (Thornberry and Lazebnik, 1998). Caspase-8 ini-
tion phase, through direct inhibition of the executioner
tiates the extrinsic apoptotic pathway by integrating
caspases-3 and/or -7. In addition, they prevent initiation
apoptotic signals transduced by cell surface death re- of the intrinsic (postmitochondrial) apoptotic pathway
ceptors (Krammer, 2000). Caspase-9 initiates the intrin- by direct inhibition of the apical caspase-9. Human XIAP
sic apoptotic pathway to delete superfluous cells of (Deveraux et al., 1997), cIAP1, and cIAP2 (Roy et al.,
the developing mammalian nervous system, and also in 1997; Deveraux et al., 1998) can inhibit caspases-3, -7,
response to cellular damage (Nicholson, 1999). Both and -9, but not caspases-1, -6, or -8. MLIAP/Livin shows
initiator caspases converge on the activation of the exe- weak inhibition of caspase-3, but more robust inhibition
cutioner caspases-3 and -7, which together cleave the of caspase-9 (Kasof and Gomes, 2000; Vucic et al.,
many protein substrates that define the effector arm of 2000).
apoptosis (Nicholson, 1999). The critical role of these Dissection of XIAP reveals that the caspase-3/7 inhibi-
caspases in transmitting death signals is underscored tory segment is distinct from the caspase-9 inhibitory
by the results of gene ablation experiments in mice region. As previously demonstrated (Takahashi et al.,
where the phenotypes are very gross, evidently antiapo- 1998; Sun et al., 1999), the caspase-3 and -7 inhibitory
ptotic, and vary from early embryonic lethality (cas- function of XIAP can be traced to residues 163–240 of
pases-7 and -8) to perinatal lethality (caspases-3 and the 497 residue protein, a region that encompasses the
-9) (Kuida et al., 1996, 1998; Hakem et al., 1998; Varfolo- second BIR domain, and an N-terminal extension, resi-
dues 124–162 (a combination defined here as BIR2),
whereas a region encompassing the third BIR domain‡ To whom correspondence should be addressed (e-mail: gsalvesen@
burnham.org). (residues 252–356) inhibits caspase-9 (Deveraux et al.,
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Table 1. Summary of Crystallographic Analysis
Native Peak Edge Remote
(l 5 1.08 A˚) (l 5 1.282 A˚) (l 5 1.283 A˚) (l 5 1.181 A˚)
Data set
Resolution (A˚) 2.7 2.8 2.8 2.8
Number of reflections
Measured 174,633 84,386 84,839 81,987
Unique 27,119 23,991 24,035 23,817
Percent observed 99.4 (99.3) 95.8 (91.3) 95.9 (91.5) 96.4 (95.7)
Rmerge (%)a 6.2 (42.4) 6.6 (42.3) 6.5 (46.7) 6.2 (45.4)
MAD Phasing 20 to 2.8 A˚
Figure of merit 38.6
Space group P212121
a, b, c 70.5, 95.5, 144.2
Refinement








a Rmerge 5 SjI 2 ,I.j/SI, where I is the observed intensity and ,I. is the average intensity from multiple observations of symmetry-related
reflections, the value in parentheses correspond to the highest resolution shell.
b Rcryst 5 Sj(Fobs) 2 (Fcalc)j/S(Fobs).
c Rfree 5 same as Rcryst but comprises a test set (5% of total reflections), which was not used in model refinement.
1999; Sun et al., 2000). BIR2 inhibits caspases-3 and -7 ble. Each catalytic site is occupied by one BIR2 mole-
cule, resulting in a 95 kDa complex with dimensions ofwith apparent binding constants in the nanomolar range,
accounting for the tight binding of the parent protein. 100 A˚ 3 60 A˚ 3 60 A˚. Despite different packing interac-
tions, the structures of both inhibitor molecules in theThe BIR domain is a compact 70 residue zinc finger
comprising 3 b strands and 4 a helices, characterized asymmetric unit are almost identical, with the exception
of a 10 residue loop distal to the BIR/caspase interactionby the conservation of critical Cys and His residues that
coordinate the zinc atom (Hinds et al., 1999; Sun et al., site. The core BIR domain (residues 163–240) closely
resembles its solution structure (Sun et al., 1999) and1999; Chantalat et al., 2000; Muchmore et al., 2000;
Verdecia et al., 2000). In addition to binding caspases, other BIR domains (Hinds et al., 1999; Sun et al., 1999;
Chantalat et al., 2000; Muchmore et al., 2000; VerdeciaBIR domains can also interact with the protein Smac
(Du et al., 2000) (also known as DIABLO [Verhagen et et al., 2000), indicating that this type of domain maintains
its rigid state in the presence of its cognate ligand. Yetal., 2000]) to antagonize caspase binding, and thereby
promote apoptosis. The structures of BIR3/Smac com- the N-terminal region (residues 124–162) differs. This
region is mainly flexible in the BIR2 solution structure,plexes have been solved (Liu et al., 2000; Wu et al.,
2000), but the mode of inhibition of caspases by IAPs while it is well defined in the complex. BIR2 in complex
with caspase-3 has two additional helical turn regionswas previously unknown. To determine the mechanism,
we have performed detailed kinetic analysis of the inter- (residues 150–152 and 158–161) not observed in solu-
tion, demonstrating that complex formation inducesaction of BIR2 with caspases-3 and -7, and obtained
the crystal structure of caspase-3 in complex with BIR2. conformational stabilization of the N-terminal region.
Binding of the InhibitorResults and Discussion
The inhibitor binds across the caspase-3 substrate bind-
ing site in an elongated manner, leaving a footprint ofCrystal Structure of the BIR2/Caspase-3 Complex
Crystals of the BIR2/caspase-3 complex (Table 1) con- 12 3 35 A˚2. The interactions between both molecules
comprise about 200 non-hydrogen atoms, excluding atain two caspase catalytic domains and two BIR2 do-
mains per asymmetric unit (Figure 1). Each caspase ca- surface of 2600 A˚2 that involves three interaction sites.
Parts of the globular BIR domain and residues upstreamtalytic domain is composed of a large and a small
subunit, cleaved at the intradomain site, IETD. The two (the “sinker”) provide a core of one binding motif, while
the N-terminal helix acts as the core of the second bind-caspase-3 catalytic domains are structurally identical
(RMS deviation for Ca positions 5 0.43 A˚). They form a ing unit (the “hook”) (Figure 2A).
The first interaction site involves the hook of BIR2functional dimer with two active sites, and the overall
structure is very similar to other caspase-3 structures (residues 138–146). A hydrophobic cluster made by the
caspase-3 residues L290, Y338, W340, and F381h en-(Rotonda et al., 1996; Mittl et al., 1997). The caspase-3
mutant used in this study contained the natural 28 resi- gages the BIR2 residues L140, V146, and L141 (Figure
2C). A network of hydrogen bonds from T143, G144,due N-terminal propeptide. No density could be found
for those residues, indicating that they are highly flexi- and V146 also contribute to the interaction. The impor-
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Figure 2. Details of the Contacts between BIR2 and Caspase-3
(A) Overview of the inhibited caspase. The chain trace of BIR2 isFigure 1. Standard View of Caspase-3 with BIR2 Domains Bound
shown in green, running from the right (N-terminal) to the left
The asymmetric unit is composed of two caspase-3 catalytic do- (C-terminal) with the hook, line, sinker, and BIR substructures identi-
mains (blue and purple), each one binding a BIR2 molecule (green). fied. It binds backward compared to the usual direction of protein
The large and small subunits of each catalytic domain are shaded substrates. Contacts are made with both the large caspase-3 sub-
differently. Each BIR2 molecule constitutes a globular domain and unit (dark blue), the small caspase-3 subunit (light blue) of the inhib-
an N-terminal extension occupying the catalytic edge of each cas- ited caspase-3 catalytic domain (unit A), and also with a short stretch
pase. The pink sphere at the core of each BIR domain is the zinc of the adjacent caspase-3 domain (unit B, gray).
atom. (B) Interactions between caspase-3 and the sinker and BIR domain.
The major interactions from the sinker are hydrophobic, with two
isoleucine side chains (I149 and I153), Y154 and the stem of R156
(gray sticks), attached to hydrophobic residues of the 381 loop oftance of the hydrophobic interactions is demonstrated
caspase-3 (purple patch). Two hydrophobic interactions from BIRby the BIR2 mutation L141A, which abolishes inhibitory
side chains contribute F228 and the stem of R233, with a hydropho-activity (Sun et al., 1999).
bic patch underneath the main chain of BIR2. H bonds are donatedFrom the hook, the two peptide bonds on either side
by D148 from the sinker.
of the V147 Ca (the “line”) stretch across the caspase (C) The N-terminal hook comprises the first major binding unit. Two
substrate binding cleft, leading to the “sinker” just be- leucine side chains (L140 and L141) and V146 (all in gray sticks) in
the hook form an interaction with a hydrophobic patch (purple) onfore the globular BIR domain. The second major interac-
the surface of caspase-3, helping to align the helix.tion site comprises the sinker (residues 148–156), and
(D) Interaction of caspase unit B with BIR unit A, with the surfacepart of the BIR domain itself, which make both hy-
representing the BIR domain. The N-terminal residues of the smalldrophobic and H-bond interactions (Figure 2B). The cas-
caspase subunit of unit B (sticks) interface with the BIR unit A (gray
pase-3 residues F381b and F381d and the BIR2 residues surface). M316 sits in a hydrophobic pocket at the BIR-caspase
I149 and I153 form a hydrophobic cluster. The mutation interface close to the zinc motif, and H319 forms an H bond with
N226 of the BIR domain.of I149 reduces the activity of BIR2, although the effect
is less drastic than the mutation of L141 (Sun et al.,
1999). A key residue is D148, which provides not only
H bonds to the caspase (R341, S343, W348, and F381b), of caspase-3, which would explain the total loss of inhib-
itory activity of a D148A mutant (Sun et al., 1999).but also forms a buried salt bridge with R233 at the C
terminus of the BIR domain. This interaction is likely to The major direct contacts from the BIR domain are
from the two residues on either side of the final Zn-be critical for locking the BIR domain against the side
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Figure 3. Interactions with the Smac Pocket
(A) Cross-domain interactions of caspase-3
with BIR2 stabilize the N terminus of the cas-
pase-3 small subunit. Two adjacent BIR2 do-
mains are rendered with an electrostatic sur-
face, and the associated caspase-3 large
subunits (purple) and small subunits (cyan)
are shown in Ca trace. The N-terminal four
residues of the caspase small subunits in the
crystal all lie in a pocket on the adjacent BIR
domain. This pocket is topologically equiva-
lent to the Smac pocket of BIR3. The inter-
acting portions are highlighted in yellow.
(B) BIR2 and BIR3 domains have been super-
imposed, and the BIR2 surface rendered to
show charged residues. The N terminus of
the small subunit of caspase-3 (blue) matches
well with the Smac N terminus (white). The
N terminus of the caspase small subunit is
surrounded by the acidic patch comprising
E211, D214, and E219.
(C) Cleavage sites in the interdomain linker of
human caspases are identified. The primary
caspase processing sites are highlighted in
red, and the four residues compatible with
binding in the Smac pockets of BIR domains
are highlighted in green. The secondary
cleavage site is highlighted in purple. Cleav-
age at the secondary site, which occurs dur-
ing apoptosis, would shorten the caspase-
3, -7, and -9 small subunit N-terminals such
that they would not be long enough to stretch
across to the Smac pocket of adjacent BIR
domains.
coordinating cysteine, C227, which contact residues sition of the BIR3/Smac structure with BIR2 reveals a
topologically equivalent pocket with strong chemical316–318 at the N terminus of the small subunit of the
second catalytic domain of the caspase dimer (Fig- similarities (Figure 3B). The pocket in BIR2 is occupied
by the N terminus of the adjacent caspase-3 small sub-ure 2D).
The N terminus of the small caspase-3 subunit is dis- unit. The three N-terminal residues of Smac and cas-
pase-3 superimpose well. In both structures, the posi-ordered in all previous structures, but in the structure
reported here, we traced the polypeptide chain through tively charged N-terminal amino group is sandwiched
between two residues, D214 and E219 (BIR2) or E314to its N terminus. This is due to the stabilizing interac-
tions with a symmetry-related molecule in the crystal and Q319 (BIR3). This ionic interaction is followed by a
short antiparallel b-sheet-like structure. Residues V312lattice (Figure 3A). Inspection of this interaction revealed
that the N terminus binds into the putative Smac pocket of caspase-3 and P3 of Smac occupy a similar position
(Figure 3B). Interestingly, an alignment of activationof BIR2.
cleavage sites in caspases (Figure 3C) shows that the
four N-terminal residues of the small subunit of cas-Interactions in the Smac Pocket
Smac is a mitochondrial protein that has been demon- pases-3, -7 and -9 are sterically capable of binding to
the Smac site. Interestingly, caspases-2, -6 and -8,strated to accelerate apoptosis by sequestering IAPs
so that they can no longer inhibit caspases (Du et al., which are not inhibited by IAPs, lack similar sequences.
The BIR-antagonist action of Smac has been sug-2000; Verhagen et al., 2000), and the interaction site has
been traced to a pocket on BIR3 that accepts the Smac gested to be due to an overlap with caspase interaction
sites (Liu et al., 2000; Wu et al., 2000). In modeling theN terminus (Liu et al., 2000; Wu et al., 2000). Superimpo-
IAP Interaction with Caspases
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trimolecular complex of Smac/BIR/caspase based on rived value (koff 5 1.2 3 1023 s21) confirming the simple
reversibility of the interaction (see Experimental Proce-the Smac/BIR3 structures we can see how steric clashes
from Smac would preclude caspase-3 from binding to dures). The complex between BIR2 and caspase-3 or
-7 was observed under nondenaturing conditions (Fig-BIR2. However, it is not clear how simple oligopeptides
mimicking the Smac N terminus (Srinivasula et al., 2000) ure 4C). Complexes of caspase-3 or -7 with BIR2 are
dissociated to their constituent subunits in SDS-PAGE.would accomplish this, since the Smac interaction site
is separate from the BIR2 interaction site (Figure 3A). No cleavage of the BIR2 protein was observed in any
of these interactions, as BIR2 was seen to remain as a
single 17 kDa band in SDS-PAGE, indicating that theSpecificity of BIR2 for Caspases
catalytic apparatus of caspases is not required for inhibi-The interactions demonstrated in Figure 2 account for
tion by BIR2. These data show BIR2 to be a rapid, tightthe inhibition of caspase-3 and probably also for its
binding, noncovalent, and fully reversible inhibitor ofclosest relative, caspase-7. However, no other known
caspase-3 and -7, consistent with the lack of covalentcaspases are inhibited (Deveraux et al., 1997, 1999). To
interactions between the inhibitor and enzyme revealedunderstand the structural basis of this selectivity, we
in the structure.superimposed the structures of caspase-8 (Blanchard
et al., 1999; Watt et al., 1999) and caspase-9 (M. R.,
unpublished data) onto the BIR2/caspase-3 structure. Differences between BIR2 and Peptide Inhibitors
Although synthetic peptidyl inhibitors of caspase-3 (Ro-The lack of binding to caspase-8 and -9 is readily ex-
plained by the absence of the hydrophobic pattern of tonda et al., 1996; Mittl et al., 1997) and the hook-line-
sinker of BIR2 both occupy the active site, the modesthe 381 loop, such that important interactions with the
hook and sinker of BIR2 cannot form. On the other hand, of interaction and mechanism of inhibition are very dif-
ferent. The peptidyl inhibitors (such as DEVD-aldehydethe third BIR domain of XIAP (BIR3) selectively inhibits
caspase-9 (Deveraux et al., 1999; Sun et al., 2000), and and DEVD-fmk) bind in the same way as substrates,
and utilize the catalytic function of caspases to achieveso we modeled the interaction of caspase-9 and BIR3
based on our structure of the BIR2/caspase-3 complex. binding, acting as transition state analogs or covalent
modifiers. They fully occupy the substrate binding sites.BIR3 could be readily docked to caspase-9 in the same
orientation of the BIR2/caspase-3 complex, but changes The arrangement of the hook not only precludes the
approach of the BIR2 chain to the catalytic center, butin the orientation of the C-terminal helix of BIR3 would
have to be made to explain the critical interactions pre- also impedes occupancy of the S1, S2, and S3 substrate
recognition sites. In the DEVD structures, an Asp sidedicted by mutagenesis experiments (Sun et al., 2000).
Moreover, inhibition of caspase-9 does occur in the ab- chain occupies the S1 pocket, and this is replaced in
the BIR2 structure by a water molecule. The S2 pocketsence of a region of BIR3 equivalent to the hook of BIR2
(Sun et al., 2000). Thus, differences must exist in the is blocked by a caspase side chain in the BIR2 complex
(Figure 4B). Here, the side chain of Y338 occupies thebinding mode of BIR3 and caspase-3, but these can, in
principle, be accommodated within the frame of the volume corresponding to the S2 site due to an 858 rota-
tion around x1 compared to the DEVD-bound structuresBIR2/caspase-3 orientation.
(Rotonda et al., 1996; Mittl et al., 1997). The rotation of
Y338 implies that either the ground state of the enzymeMechanism of Inhibition
contains a blocked S2 subsite that opens during sub-The first step in peptide bond hydrolysis is acylation of
strate binding, or that the interaction of BIR2 forcesa protein carbonyl. The hook adopts a structure that
Y338 down to block the preexisting pocket. Interest-precludes the first step; all the potential carbonyls are
ingly, Y338 and its neighbor F381h are the only non-too far away to be attacked by the catalytic Cys of
surface caspase side chains that are altered by BIR2caspase-3 (Figure 4A), and a steric blockade is imposed
binding. The only interaction that can be consideredon the active site. This explains why the catalytic mutant
equivalent between the two modes of inhibitor bindingof caspase-3 binds, since the natural catalytic Cys does
is within the S4 subsite, which in caspase-3 and -7 isnot participate in the interaction. In addition, BIR2 binds
highly specific for Asp side chains (Thornberry et al.,in a reverse orientation with respect to substrates such
1997). In the crystal structure, D148 of BIR2 occupiesthat even if acylation occurred, hydrolysis by the normal
the S4 pocket (Figure 4B), which is occupied by a topo-mechanism would be impossible. The structure also ex-
logically equivalent Asp in the DEVD structures.plains why caspase-3 treated by Z-VAD-fmk is unable
Overall, the solution adopted by BIR2 to the problemto bind BIR2 (Figure 4C and Sun et al., 1999), since
of specifically inhibiting caspase-3 and -7 bears almostthere would be severe clashes with the bound inhibitor,
no relationship to the mechanism of substrate analogs.displacing the hook and line of BIR2.
Interestingly, it is also much more selective, since theThese molecular interactions nicely explain the inhibi-
analogs react with almost all caspases (Garcia-Calvo ettion kinetics between BIR2 and caspases. Both cas-
al., 1998), whereas BIR2 is only known to inhibit cas-pase-3 and -7 are tightly bound, with caspase-7 being
pase-3 and its close relative, caspase-7 (Deveraux etmore efficiently inhibited (Table 2). The different inhibi-
al., 1999).tion constants (Ki) are determined primarily by associa-
tion rates (kon), with BIR2 reacting significantly faster
with caspase-7 than with caspase-3. The dissociation Comparison with Other Protease Inhibitors
There are at least two properties of BIR2 that restrainrates (koff) were estimated as a product of Ki and kon,
assuming a simple reversible interaction. The estimated cleavage: its reverse binding and the prevention of ap-
proach to the catalytic center. The overall inhibitory con-dissociation rate agreed well with an experimentally de-
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Figure 4. Mechanism of Inhibition
(A) The BIR2 hook region (green) is superimposed on the structure of the substrate analog DEVD-aldehyde (in brown) bound to caspase-3,
with its catalytic residues H237 and C285 shown in gray (1PAU; Rotonda et al., 1996). The distance from Sg of the catalytic Cys to the carbonyl
carbon of the substrate analog is 1.8 A˚, but the closest approach of a BIR2 carbonyl is 5.8 A˚, well out of the reach of atomic interactions.
(B) Focus on the substrate binding region of caspase-3, and comparison of DEVD-aldehyde and BIR2 binding interactions. The trace of BIR2
(green) is superimposed on the caspase-3 structure with DEVD-aldehyde (brown) bound. Two caspase-3 side chains (Y338 and F381h) that
occupy different rotamers in the two complexes are highlighted. In blue is their position in the BIR2 structure, and in gray is their position in
the DEVD-aldehyde structure. To the left of the panel the side chain of D148 of BIR2 and the topologically equivalent P4 Asp residue of DEVD-
aldehyde are shown.
(C) The interaction between BIR and caspase-3 or -7 was observed by nondenaturing and SDS-PAGE. A 1.2-fold molar excess of BIR2 was
incubated with wild-type (wt) caspase-3 or caspase-7, or C285A caspase-3 (mut), and complex formation visualized as a gel shift in nondenatur-
ing PAGE. Binding of BIR2 could be prevented by pretreating caspase-3 with Z-VAD-fmk. The complex was dissociated in SDS-PAGE (top
panel), and no cleavage of BIR2 was observed.
IAP Interaction with Caspases
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Table 2. Inhibition Parameters of BIR2 on Caspase-3 and Caspase-7
Ki (M) kon (M21 s21) Calculated koff (s21)
Caspase-3 9.7 (65.0) 3 10210 2.5 (61.0) 3 106 2.4 3 1023
Caspase-7 1.0 (60.4) 3 10210 1.4 (60.5) 3 107 1.4 3 1023
Ki and kon values are given as 6 standard deviation of three data sets.
formation is summarized in Figure 5. Almost all natural reverse orientation to a second site on the surface of
the enzyme, the exosite, that tightens the inhibitory inter-protease inhibitors prevent access of substrates to the
proteases’ catalytic centers by steric hindrance, and action (Rydel et al., 1990), somewhat similar in principle
to the BIR interaction with caspase-3.have adopted a range of divergent mechanisms to ac-
complish this goal. However, the BIR2 mechanism ap- Perhaps the closest similarity between the BIR2 inhibi-
tory mechanism and other known protein:protease inter-pears unique. Members of the kunitz and kazal family
of serine protease inhibitors, for example, bind in the actions is seen in the zymogens of members of the
papain family of cysteine proteases. These zymogenssame orientation as substrates (Bode and Huber, 1991).
Inhibition is created by rigidity of the frame, which does contain a fully formed active site that is blocked by the
N-terminal propeptide (Turk et al., 2000). The prodomainnot allow approach to the transition state (Read and
James, 1986). The TIMPs inhibit their target matrix met- contains a helix at the top of the catalytic site that contin-
ues through the protease specificity sites in reverse di-alloproteases by occupying the binding cleft in a similar
substrate-like manner, but catalysis is prevented by co- rection compared with substrates. Though the nature
of the contacts and organization of the prodomain areordination of the critical zinc of the protease by an inhibi-
tor side chain (Bode and Huber, 2000). Other inhibitors completely different to BIR2, it is interesting that the
two completely unrelated families of cysteine proteasesof serine proteases, notably the serpins, allow the initial
step in cleavage, but trap the acyl enzyme intermediate have converged on a comparable mechanism for ablat-
ing activity. Of course, the papain family prodomains(Huntington et al., 2000). Indeed, this may explain the
mechanism of the caspase inhibitor CrmA (which is a exist to regulate the activation of the enzymes, whereas
BIR2 exists to ensure the inhibition of caspases, but theserpin) and possibly also baculovirus p35, since both
appear to require cleavage for their function. However, similarities are nonetheless intriguing.
trapping of acyl enzymes by suicide inhibition, as it is
sometimes called (Patston et al., 1991), applies only Conclusions
to serpins and p35, and other inhibitor families have
adopted ingenious strategies for protease inhibition. The inhibition of caspase-3 by BIR2 demonstrates clas-
sic reversible tight binding kinetics, and this is explainedThe cystatin family of cysteine protease inhibitors
function in part by using a similar mechanism to that of by the noncovalent blocking of the active site by a novel
structure, the helical hook. The hook is necessary, butBIR2, as they do not conform to the substrate pockets
not sufficient, since mutations in either the hook or theand place a structure distant from the catalytic center
sinker eliminate inhibition (Sun et al., 1999). However,(Stubbs et al., 1990). Yet the cystatins still interact in the
the hook-line-sinker substructures themselves are stillsame orientation as substrates. The closest similarity
not sufficient for inhibition, since a synthetic peptideamong previously known mechanisms is with some
spanning this region still does not inhibit caspase-3 (Sunthrombin inhibitors, exemplified by the medical leech-
et al., 1999). The BIR domain is required, presumably,derived protein hirudin. The N terminus of hirudin lies
to align and stabilize the main inhibitory interactions.in thrombin’s S1 pocket and the chain proceeds in a
It is clear that the cell’s solution to the problem of
how to specifically inhibit caspases does not reside in
the BIR domains, but rather in the interdomain segments
between domains. The unique solution utilizes a large
number of interactions, and abolishing even one of these
can ablate inhibition. This information, and the molecular
determinants of the interactions, will be useful in the
design of drugs that can be used to antagonize IAP
inhibition of caspases. For example, small molecules
that bind the hook or sinker will be specific for antagoniz-
ing inhibition of caspase-3 and -7 without affecting cas-
pase-9 inhibition. Such molecules would be exquisitely
specific, and may be especially useful to facilitate cas-Figure 5. Diagrammatic Representation Illustrating the Topological
pase activity by extrinsic (caspase-8) pathway triggersContacts in BIR2-Inhibited Caspase-3
in cancers where IAPs are overexpressed, without af-The substrate pockets designated by “S” have been defined on the
basis of caspase structures bound to peptidyl inhibitors. They are fecting other IAP-protein interactions.
mostly unoccupied by BIR2, with the exception of S4. The most
important inhibitory interaction comes from the hook, which ablates Experimental Procedures
catalytic activity by sterically hindering substrate access. The sinker
and BIR domain help to stabilize the complex, acting as exosite Recombinant Proteins
binding elements. The cross-unit interaction shown by the thin blue A region of XIAP that potently inhibits caspases-3 and -7 was gener-
ated by PCR from a pGEX construct containing the XIAP cDNAline may also help to stabilize the complex.
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(Takahashi et al., 1998). The fragments were ligated into the NdeI and Data Collection and Structure Solution
A first, low resolution (4 A˚) data set was collected from a frozenXhoI sites of pET23b, resulting in a construct containing residues
124–240, plus a C-terminal His-6 tag, which was used to transform crystal (using 30% [v/v] glycerol for cryo protection) on an R-AXIS
IV image plate mounted on a Rigaku rotating anode. Data wereE. coli BL21(DE3)pLysS. Protein was expressed by induction with
0.4 mM IPTG for 4 hr at 308C. The protein was purified on Ni-chelate processed with DENZO and SCALEPACK (Otwinowski and Minor,
1997). Two caspase-3 molecules (search model 1PAU, [Rotonda etSepharose (Pharmacia) from the soluble fraction of sonicated cells.
For crystallization, a BIR2 construct containing residues 124–240 al., 1996]) were located in the asymmetric unit by molecular replace-
ment using the program AmoRe (Navazza, 1994). Both rotational and(containing mutations C202A and C213G) was used (Sun et al., 1999).
Active recombinant caspases-3 and -7 were produced in E. coli translational searches gave clear peaks. After rigid body refinement
within AmoRe, the R factor dropped to 42.6%. Analysis of the crystal(Stennicke and Salvesen, 1999) and purified by Ni-chelate chroma-
tography. The active concentrations were determined by titration packing revealed that the caspase-3 molecules form dimers identi-
cal to the ones seen in other crystal structures, strongly supportingwith the irreversible caspase inhibitor Z-Val-Ala-Asp-fluoromethyl
ketone (Z-VAD-fmk, Enzyme Systems Products) as previously de- this molecular replacement solution. No crystal contacts were found
between the caspase dimers, suggesting that BIR2 was indeedscribed (Stennicke and Salvesen, 1999). The caspase-3 and -7 cata-
lytic mutants (C285A) were constructed by overlap PCR (Stennicke present in the crystals. Yet, BIR2 gave no rotational solution in
AmoRe using the NMR structure (Sun et al., 1999) as a searchet al., 1998). The catalytic mutants of caspases-3 and -7 were con-
verted by treatment with a 0.01 molar ratio granzyme B for 15 min molecule, and electron density in the expected BIR binding region
was difficult to interpret. We therefore utilized the BIR2 zinc atomsat 378C, resulting in cleavage at the interdomain linker after IETD
and IQAD, respectively. for MAD phasing.
Four data sets were collected at the SSRL (peak, inflection point
and remote on beamline 9-2 and one native data set on beamlineSpectrophotometry and Spectrofluorometry
7-1). Two zinc sites were found and MAD phases calculated withThe caspase substrate Ac-Asp-Glu-Val-Asp-p-nitroanilide (Ac-
the program SOLVE (Terwilliger and Berendzen, 1999). The mapDEVD-pNA) was purchased from Biomol and Z-Asp-Glu-Val-Asp-7-
was improved using DM (Collaborative Computational Project, 1994)amino-4-trifluoromethyl-coumarin (Z-DEVD-AFC) was from Enzyme
and then used for model building. Phase combination of experimen-Systems Products. Assays using colorimetric pNA substrates (maxi-
tal phases with molecular replacement phases was not necessarymal absorbance at 405 nm) were performed on a SpectraMAX 340
because almost all BIR2 residues could be built (following the topol-plate reader coupled with SOFTMAX software (Molecular Devices,
ogy defined by the BIR2 solution structure) in this density. An initialSunnyvale, CA). Assays using fluorogenic substrates were carried
model was refined in CNS (Brunger et al., 1998) (Rw/Rfree 5 35.6/out on Perkin-Elmer LS50B luminescence spectrometer coupled
39.6). After several cycles of model building in Main (Turk, 1992)with the FL WinLab software (Perkin Elmer Corp) or fmax Fluores-
and crystallographic refinement (simulated annealing and positionalcence Plate Reader (Molecular Devices) at excitation wavelength
and temperature-factor refinement applying NCS constrains be-400 nm and emission wavelength 505 nm. All assays were thermo-
tween the two catalytic units of caspase-3 and the two BIR2 mole-stated at 378C.
cules) in CNS (Brunger et al., 1998) using target parameters (Engh
and Huber, 1991), the R factor dropped to Rwork/Rfree 5 24.9/27.8.Inhibition Kinetics
The final model consists of two catalytic units of caspase-3 with
Inhibition rates and equilibria were determined as previously de-
two BIR2 inhibitors, and contains the following residues: 148–296
scribed (Zhou and Salvesen, 2000). For dissociation kinetics, com-
(large subunit) and 310–401 (small subunit) of caspase unit A, and
plexes were first formed by incubating the caspase with an excess
residues 127–237 of the corresponding BIR2; residues 148–297 (large
of BIR2 in assay buffer at 100-fold above the eventual assay concen-
subunit) and 310–401 (small subunit) of caspase unit B, and residues
tration, for sufficient time to ensure .99% complex formation. Fol-
135–169 and 180–236 of its BIR2. Figures were prepared using the
lowing incubation, an aliquot was diluted into a large volume of
programs Dino (DINO: Visualizing Structural Biology [2001]; http://
assay buffer containing a large excess of substrate and the assay
www.biozentrum.unibas.ch/zxray/dino), Spock (Christopher, J. A.;
started immediately. The inhibitor was diluted to around its Ki, and SPOCK: The Structural Properties Observation and Calculation Kit
the assay was followed until a new equilibrium rate was achieved
[program manual], The Center for Macromolekular Design, Texas
for a period of time.
A&M University, College Station, TX [1998]), WebLab Viewer Pro,
The integrated rate equation for the dissociation of equimolar
and Raster 3D (Merritt and Murphy, 1994).
complex (Morrison and Walsh, 1988) with a dissociation rate con-
stant koff is:
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